News
Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.
53m
Barchart on MSNThis Blue-Chip Stock Is Cooking Up a Major Growth CatalystEli Lilly and Company (LLY), one of the world’s leading pharmaceutical giants, might have just unveiled its next major growth ...
From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...
Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...
First ever daily Ozempic-like PILL helps users shed up to 2st – and could be available within months
A DAILY weight loss pill that works like Ozempic can help users shed an average of almost two stone, a study reveals. People ...
For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
Redditors are complaining their long-term Mounjaro use is causing their hair to fall out in clumps. Experts claim sorting your diet out may fix the issue.
No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results